Loading clinical trials...
Loading clinical trials...
A 26-week Double Blinded, Multiregional, Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Non-insulin Anti-diabetic Drugs, in Insulin naïve Subjects With Type 2 Diabetes.
This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will get their study medicine in an injection pen. Participants will get a pen for weekly injection and one for daily injection. One will be icodec or degludec and the other will be dummy medicine. The treatment participants get is decided by chance. Participants and the study staff will not know which active medicine they get. The insulin is injected with a needle in a skin fold in the thigh. The study could last for about 8 months. Participants will have 13 clinic visits and 17 phone calls with the study doctor. At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Lakeview Clinical Research, LLC
Guntersville, Alabama, United States
American Clinical Trials
Buena Park, California, United States
Headlands Research California, LLC
Escondido, California, United States
Valley Research
Fresno, California, United States
First Valley Medical Group
Lancaster, California, United States
Est Cst Inst for Rsrch,Jksnvil
Jacksonville, Florida, United States
Palm Harbor Medical Associates
Palm Harbor, Florida, United States
Metabolic Research Institute Inc
West Palm Beach, Florida, United States
Cedar-Crosse Research Center
Chicago, Illinois, United States
Cotton-Oneill Diabetes and End
Topeka, Kansas, United States
Start Date
March 24, 2021
Primary Completion Date
June 23, 2022
Completion Date
June 23, 2022
Last Updated
December 4, 2024
588
ACTUAL participants
Insulin icodec
DRUG
Placebo insulin icodec
DRUG
Insulin degludec
DRUG
Placebo insulin degludec
DRUG
Lead Sponsor
Novo Nordisk A/S
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062